Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits by Smith, James G.w. et al.
Stem Cell Reports
ArticleIsogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-
Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits
James G.W. Smith,1,7,10,* Thomas Owen,2,10 Jamie R. Bhagwan,1 Diogo Mosqueira,1 Elizabeth Scott,1
Ingra Mannhardt,3,8 Asha Patel,1,6 Roberto Barriales-Villa,4,5 Lorenzo Monserrat,5,9 Arne Hansen,3,8
Thomas Eschenhagen,3,8 Sian E. Harding,2 Steve Marston,2 and Chris Denning1,*
1Wolfson Centre for Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, University Park,
Nottingham NG7 2RD, UK
2National Heart and Lung Institute, Imperial College, London W12 0NN, UK
3Institute of Experimental Pharmacology and Toxicology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany
4Inherited Cardiovascular Diseases Unit, Cardiology Service, Complexo Hospitalario Universitario A Corun˜a, Servizo Galego de Sau´de (SERGAS),
Universidade da Corun˜a, A Corun˜a, Spain
5Instituto de Investigacio´n Biome´dica de A Corun˜a (INIBIC), A Corun˜a, Spain
6Department of Gene Therapy, National Heart and Lung Institute, Imperial College London SW3 6LR, UK
7Faculty of Medicine and Health Sciences, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7UQ, UK
8DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lu¨beck, Hamburg, Germany
9Health in Code S.L., Cardiology Department, A Corun˜a, Spain
10Co-first author
*Correspondence: james.smith@nottingham.ac.uk (J.G.W.S.), chris.denning@nottingham.ac.uk (C.D.)
https://doi.org/10.1016/j.stemcr.2018.10.006SUMMARYHypertrophic cardiomyopathy (HCM) is a primary disorder of contractility in heart muscle. To gain mechanistic insight and guide phar-
macological rescue, this studymodels HCMusing isogenic pairs of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) carrying the E99K-ACTC1 cardiac actin mutation. In both 3D engineered heart tissues and 2Dmonolayers, arrhythmogenesis was
evident in all E99K-ACTC1 hiPSC-CMs. Aberrant phenotypes were most common in hiPSC-CMs produced from the heterozygote father.
Unexpectedly, pathological phenotypes were less evident in E99K-expressing hiPSC-CMs from the two sons. Mechanistic insight from
Ca2+ handling expression studies prompted pharmacological rescue experiments, wherein dual dantroline/ranolazine treatment was
most effective. Our data are consistent with E99K mutant protein being a central cause of HCM but the three-way interaction between
the primary genetic lesion, background (epi)genetics, and donor patient agemay influence the pathogenic phenotype. This illustrates the
value of isogenic hiPSC-CMs in genotype-phenotype correlations.INTRODUCTION
Cardiomyopathies are defined as primary disorders of
contractility in heart muscle. Most classifications of cardio-
myopathy divide the disease into acquired and inherited
disease due to a mutation and into hypocontractile pheno-
type with reduced ejection fraction or hypercontractile
phenotype with preserved ejection fraction (Maron et al.,
2006). Hypertrophic cardiomyopathy (HCM) is a common
clinical phenotype, found in up to 1 in 500 of the general
population, and symptoms usually manifest in the second
or third decade of life. HCM is characterized by thickened
left ventricular walls, notably the interventricular septum,
and a hyperdynamic myocardium with defective relaxa-
tion, with an enhanced susceptibility to arrhythmia that
can lead to sudden death in a small proportion of patients.
In the longer term, these abnormalities can lead to heart
failure. Histologically HCM leads to myocyte disarray and
interstitial fibrosis.
HCM is overwhelmingly an inherited disease, and in
most cases mutations in one of the genes coding for the
contractile and structural proteins of the cardiac muscle1226 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018 j ª 2018
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phenotype-genotype relations in HCM is complex.
Several other inherited diseases, including restrictive
cardiomyopathy and left ventricular non-compaction
(LVNC), appear to be subsets of HCM and can share the
same mutations. Moreover, the penetrance of the HCM
phenotype is variable, since symptoms of carriers of
HCM-linked mutations can range from asymptomatic to
fatal cardiac dysfunction (Sedaghat-Hamedani et al.,
2018). Insight into the biophysical mechanism behind
cardiomyopathies has advanced significantly. It is now
clear that an enhanced myofilament Ca2+ sensitivity is
often the primary consequence of HCM mutations lead-
ing to the hyperdynamic phenotype (Spudich, 2014)
and the enhanced susceptibility to arrhythmia (Huke
and Knollmann, 2010). Yet the pathway to secondary
HCM phenotypes, such as myocyte hypertrophy, myocar-
dial disarray, and interstitial fibrosis, are not easily
explained by sarcomeric gene defects alone and may be
dependent upon genetic background.
Actin comprises the main component of the sarcomeric
thin filament, with a-cardiac actin (encoded by ACTC1;The Author(s).
ns.org/licenses/by/4.0/).
Genbank: NM_005159) accounting for 80% of actin
expression in mature cardiomyocytes (Olson et al., 1998).
To date, 14 ACTC1 mutations have been identified in
patients diagnosed with one or more forms of cardio-
myopathy, of which 11 are associated with HCM (Mogen-
sen et al., 1999; Olson et al., 1998, 2000; Morita et al.,
2008; Kaski et al., 2009; Olivotto et al., 2008). The most
extensively studied of these mutations is c.G301A
(p.Glu101Lys). Although this mutation occurs at codon
101 of the ACTC1 gene, the mature protein in muscle has
the amino acid substitution E99K due to the removal of
two N-terminal amino acids during post-translational pro-
cessing (Rubenstein and Martin, 1983).
Although mutations in ACTC1 are relatively rare, the
clinical consequences have been studied unusually thor-
oughly. Three clinical studies have all shown the E99K-
ACTC1 mutation to present varying HCM-related pheno-
types (Arad et al., 2002; Olson et al., 2000), with the most
extensive study by Monserrat et al. (2007). This found
diverse and overlapping E99K-ACTC1 phenotypes using
clinical and morphological data from 94 cases. There
were clear differences in the nature and severity of the clin-
ical expression of the disease between carriers, but none
was normal. HCM and LVNC were the most frequently re-
ported phenotypes (Monserrat et al., 2007; Song et al.,
2011). Hypertrophy was reported from 62 of 76 mutation
carriers. The distribution of the hypertrophy was predomi-
nantly apical. Electrocardiography (ECG) investigation
showed abnormalities in 53 of 61 carriers. Atrial fibrillation
or flutter was found in 7 of 53. The 22 adverse events re-
ported included eight sudden deaths (five in a single
family).
Several different E99K-ACTC1 models have been devel-
oped to investigate the mechanisms behind these disease
phenotypes. These include in vitro motility and laser trap
assays (Debold et al., 2010), and reconstitution of human
E99K-ACTC1 in the thin filament of bovine cardiac muscle
fibers (Bai et al., 2015). Studies in transgenic E99K-ACTC1
mice are themost comprehensive (Song et al., 2011). These
models have been useful in obtaining data on the proper-
ties of E99K-ACTC1, with increased Ca2+ sensitivity often
reported for the mutant protein (Song et al., 2011, 2013;
Bai et al., 2015), although this is sometimes not observed
and adds to the debate surrounding disease mechanism
(Debold et al., 2010).
Nevertheless, while the a-cardiac actin sequence is
identical in human and mouse, conclusions are still
limited by the predominance of the a-myosin heavy
chain isoform in the ventricles of mice versus the b iso-
form in humans. Differing levels of mutant sarcomeric
transcripts than those occurring from a single mutant
allele in human expression, and intrinsic differences
in cardiac function between the species, including a10-fold higher heart rate compared with humans, are
important (Arad et al., 2002; Denning et al., 2016). There
is need for a fully human in vitro E99K-ACTC1 model, in
which protein interaction data can be more readily
related to the patient phenotype and used to explain var-
ied disease penetrance.
Here, we developed a human model of HCM by harness-
ing human induced pluripotent stem cell (hiPSC) reprog-
ramming and CRISPR/Cas9 genome editing technology.
By generating hiPSC lines from patients carrying the
E99K mutation (E99K1 and E99K2) and a healthy non-car-
rier relative (NC) and then using CRISPR/Cas9 technology,
we created a model whereby the mutation had been
corrected in two isogenic pairs and introduced in the
other. This model recapitulated many disease pheno-
types including abnormal contractility, Ca2+ sensitivity/
handling, arrhythmogenesis, and hypertrophic signaling.
In almost all cases the aberrant phenotypes observed in
E99K-expressing hiPSC-derived cardiomyocytes (hiPSC-
CMs) were greater than in non-expressing isogenic coun-
terparts, consistent with this mutant protein having a
central role in HCM.
However, there were considerable variations in severity
between the lines, most notably with hiPSC-CM pheno-
types from the heterozygote father beingmost pronounced
andwidespread. This included contraction force and veloc-
ity, and relaxation time; hypersensitivity to low Ca2+; Ca2+
handling (contraction and relaxation); hypertrophic brain
natriuretic peptide (BNP) expression; and expression of
Ca2+ handling machinery (CASQ2, CALM1, CAMK2D,
PPP3cA). Although we had not expected this, it may be
attributed to the greater age of the father relative to his
sons. Nevertheless, the E99K mutation perturbed Ca2+
signaling pathways in some instances, which enabled
hypothesis-driven drug rescue experiments. Thus the
Ca2+ handling modifier drugs, ranolazine and dantrolene,
reduced hypertrophic signaling, with dual treatment being
most effective.RESULTS
Generation of Isogenic Sets of E99K-ACTC1 hiPSCs by
CRISPR/Cas9 Editing
Skin-punch biopsies were obtained and reprogrammed to
hiPSCs from three donors of the same family; a 48-year-
old male patient carrying the c.ACTC1G301A mutation
(E99K1), the 14-year-old healthy c.ACTC1G301G son (NC),
and the 19-year-old son carrying the c.ACTC1G301A muta-
tion (E99K2) (Figure S1). The resulting hiPSC lines
expressed the OCT4 pluripotency marker (Figure 1A)
and had the expected heterozygote mutant (E99K1;
E99K2) or wild-type (NC) ACTC1 sequences (Figure 1B).Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018 1227
Figure 1. Production of hiPSC Cardiomyocytes with or without c.301G>A E99K Mutations
(A) Relatives with (E99K1, E99K2) or without (NC) the mutation donated skin biopsies. Fibroblasts were reprogrammed into hiPSC using
non-integrating CytoTune 2.0 Sendai virus and E6/E8 culture medium and stained for pluripotency marker, OCT4 (green; blue is DAPI).
(B–D) In (B), sequencing confirmed the (C)301G>A ACTC1 mutation that causes the E99K polymorphic variant in diseased, but not healthy,
lines. In (C), high-efficiency differentiation of hiPSC yielded cardiomyocyte purities of >90% (red is a-actinin staining; blue is DAPI).
Counterstaining (green) with an antibody specific to the mutant E99K peptide showed that 50% of the diseased cardiomyocytes were
positive, suggesting biallelic expression of both mutant and healthy alleles (C and D). In contrast, E99K reactivity was not detected in
hiPSC cardiomyocytes from the healthy individual (C and D). n = 6.
Scale bars, 100 mm (A) and 50 mm (C). Significance was determined by Student’s t test, ***p < 0.001.Differentiation to high purity (>90% a-actinin+) cardio-
myocytes (hiPSC-CMs) (Figures 1C and 1D) allowed reac-
tivity to an antibody specific to the mutant E99K peptide
to be tested. This showed positive protein expression in
50% of the E99K1 and E99K2 hiPSC-CMs, suggesting
that only one allele of the ACTC1 gene is active in any
given cell. As expected, E99K peptide reactivity was not de-
tected in NC hiPSC-CMs (Figures 1C and 1D).1228 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018Isogenic controls were generated for E99K1, NC, and
E99K2 hiPSCs using a footprint-free PiggyBac based
CRISPR/Cas9strategy, coupled with PCR screening and
sequence confirmation (Kondrashov et al., 2018) (Fig-
ure 2A). This identified targeted clones for E99K1 and
E99K2where the c.301G>AACTC1mutation had been cor-
rected (producing E99K1-Corr and E99K2-Corr) and intro-
duced into one allele of NC (producing NC-Edit-E99K)
Figure 2. Generation of Isogenic E99K hiPSC Cardiomyocytes
(A) A footprint-free PiggyBac targeting strategy of the ACTC1 gene was used to correct or induce E99K mutation into hiPSC lines.
(B–D) In (B), sequencing confirmed the (C)301G>A ACTC1 mutation had been corrected in E99K1 and E99K2 and introduced in NC. In (C),
high-efficiency differentiation of hiPSC still yielded cardiomyocyte purities of >90% after gene editing (red is a-actinin staining; blue is
DAPI). Counterstaining (green) with an antibody specific to the mutant E99K peptide confirmed protein expression was lost in diseased
patients (C and D). In contrast, E99K reactivity was now detected in hiPSC cardiomyocytes from the healthy individual (C and D). n = 6.
Scale bars, 50 mm.
Significance was determined by Student’s t test, ***p < 0.001.(Figure 2B). Analysis by PCR of six potential mismatched
guide sequences indicated that no off-target events had
occurred in other genes (Figure S2).
These clonal lines still yielded high purity (>90% a-acti-
nin+) hiPSC-CMs. However, E99K peptide reactivity was
no longer detected in E99K1-Corr and E99K2-Corr, but
was now present in 50% of the NC-Edit-E99K hiPSC-CMs. This confirmed successful genomic editing correlated
with altered protein isoform expression, generating
isogenic control lines (E99K1-Corr, E99K2-Corr, and NC-
Edit-E99K) (Figures 2C and 2D). Thus, a suite of three
isogenic pairs comprising six hiPSC lines was successfully
created: E99K1 and E99K1-Corr; NC and NC-Edit-E99K;
and E99K2 and E99K2-Corr.Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018 1229
Figure 3. Stimulated Contraction of Isogenic Pairs of hiPSC-CM EHTs
Auxotonic EHT contractions were recorded at 100 frames per second under stimulated conditions (1 Hz). Stimulated contraction force (A),
contraction velocity (B), relaxation velocity (C), and length of contraction (D) are shown. All error bars represent SEM.
Significance was determined by Student’s t test, *p < 0.05 and ***p < 0.001. n = 10 E99K1, 10 E99K1-Corr, 11 NC-Edit-E99K, 11 NC,
5 E99K2, and 7 E99K2-Corr. Red, mutant ACTC E99K; black, wild-type. See also Figure S6.Contractility in Wild-Type and E99K EHT
hiPSC-CMs were successfully encapsulated into human
engineered heart tissues (hEHTs), matured for 2 weeks,
and stimulated at 1Hz.We used image analysis of videomi-
croscopy for the calculation of contraction parameters as
previously described (Eschenhagen et al., 2012). E99K1
had significantly stronger contractions than E99K1-Corr1230 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018(Figure 3A); however; there was no significant difference
between NC and NC-Edit-E99K lines, and E99K2 generated
significantly less force than its corrected control.
Although the E99K1 line generated significantly more
force, the overall length of contraction time was similar
to E99K1-Corr. However, both NC-Edit-E99K and E99K2
lines had significantly longer contraction times than their
Figure 4. Ca2+ Sensitivity of Isogenic Pairs of hiPSC-CM EHTs
iPSC-CM EHT were exposed to increasing concentrations of Ca2+ in Tyrode’s solution and contractions were recorded while being stimulated
at 1 Hz. In (Ai), the force of EHTs was calculated as a percentage of maximum for the unedited lines, with E99K lines shown in red and wild-
type in black. EC50 values were calculated using absolute force and are shown for the unedited lines in (Aii). The comparison of normalized
forces are shown for the isogenic pairs of E99K1 (Bi), NC (Bii), and E99K2 (Biii); the dotted line is the average with arrhythmogenic EHTs
removed. In (Ci) to (Ciii), the corresponding EC50 values for isogenic lines were calculated using absolute force.
All error bars represent SEM. Significance was determined by Student’s t test and one-way ANOVA, *p < 0.05, ++p < 0.01, and +++p < 0.001.
n = 7 E99K1, 2 E99K1-Corr, 7 NC-Edit-E99K, 7 NC, 5 E99K2, and 6 E99K2-Corr. Red, mutant ACTC E99K; black, wild-type.wild-type isogenic controls (Figure 3D). When contraction
and relaxation velocities were analyzed, E99K1 line had
significantly faster speeds than their corrected counterpart.
In contrast, NC-Edit-E99K and E99K2 were similar or
significantly slower (Figures 3B and 3C). Thus, there were
differences between E99K1 hEHT responses relative to
NC-Edit-E99K- or E99K2-derived hEHTs.
In previous studies the E99K-ACTC1 hypercontractile
phenotype was shown to be due to an increase in myofi-
brillar Ca2+ sensitivity (Song et al., 2011, 2013). We there-
fore studied the effect of external Ca2+ concentration on
EHT contractility (Figure 4). At 0 mM Ca2+ all EHTs were
quiescent, whereas all were spontaneously beating at0.5 mM Ca2+. Increased [Ca2+ ] dependence was seen
when comparing unedited E99K lines (E99K1 and E99K2)
against the unedited wild-type NC line in both normalized
contraction amplitude at different Ca2+ concentrations
and in their EC50 values (Figures 4Ai and 4Aii). However,
when comparing each line with its isogenic counterpart,
increased contraction at lower Ca2+ concentrations was
not seen in any of the three pairs, and neither were
changes in EC50 values (Figures 4Bi–4iii and 4Ci–4iii).
Thus, overall we could detect increased [Ca2+] dependence
in the uneditedmutant lines compared with wild-type, but
this phenotype was not knocked in or corrected in the
isogenic pairs.Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018 1231
E99K hiPSC-CMs Display Increased Arrhythmogenic
Events
We next investigated whether E99K-ACTC1 mutants
showed any difference in arrhythmogenic event frequency,
since clinical and animal studies usually show ECG abnor-
malities and a varying degree of enhanced arrhythmia in
mutation carriers (Arad et al., 2002; Olson et al., 2000;
Monserrat et al., 2007; Song et al., 2011; Rowlands et al.,
2017). Contraction traces obtained for EHTs clearly high-
lighted the presence of arrhythmogenic events (Figure 5A).
To quantify these arrhythmogenic events in a non-biased
manner, we used pClamp software as an unbiased method
for analysis. First, the total twitch duration (combined
contraction and relaxation time) was calculated for 211
E99K1, 218 NC, and 213 E99K2 wild-type contractions in
seven EHTs. Twitch durations were averaged and found to
be significantly different (p < 0.001) between the wild-
type lines, at 0.51s for E99K1-Corr, 0.73s for NC, and
0.60 for E99K2 (Figure S3A).
Analysis then identified the number of abnormal con-
tractions that failed to return to non-arrhythmogenic
contraction time baseline during a normal event time (Fig-
ure 5B). For E99K1, 31% of contractions were found to be
abnormal, although this was not significantly different
when compared with wild-type isogenic controls (Fig-
ure 5Ci). NC-Edit-E99K and E99K2 had significantly more
abnormal contractions when compared with their wild-
type isogenic controls, with 54% and 46% abnormal
contractions, respectively (Figures 5Cii and 5Ciii). No sig-
nificant difference in the number of abnormal contractions
was found between wild-type lines, with 18%, 17%, and
14% abnormal contractions for E99K1-Corr, NC, and
E99K2-Corr, respectively.
We next evaluated whether Ca2+ concentration influ-
enced arrhythmogenesis in EHTs fabricated from the six
lines (Figure 5D). Relative to their wild-type isogenic
counterparts, all E99K hEHTs showed more arrhythmo-
genic contractions, although significance was reached at
differing Ca2+ levels. Thus, for E99K1 it was 3 mM Ca2+
for NC-Edit-E99K 0.5 mM and 1.5 mM Ca2+, and for
E99K2 3 mM and 5 mM Ca2+.
To further support the 3D arrhythmogenic analysis, we
implemented an alternative approach in a complementary
2D system. Nickase CRISPR/Cas9 was used to insert genet-
ically encoded Ca2+ indicators (R-GECO1/GEM-GECO)
into the safe locus AAVS1 of the four parental and engi-
neered hiPSC lines of E99K1 and NC. Correct insertion
was confirmed by PCR and sequencing, while expression
was validated by immunocytochemistry (Figure S4).
Confocal line scans were taken during a 300-s time period
to obtain traces and corresponding kymographs of sponta-
neous Ca2+ transients in hiPSC-CMs (Figures S4E and S4F).
These line scans were used to calculate mean peak ampli-1232 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018tudes and irregular delayed-after-depolarization Ca2+
transient events (events lower than 75% mean peak
amplitude).
In 2D culture, arrhythmogenic events were shown to
vary even at physiological Ca2+ concentration (1.8 mM),
occurring at a frequency of 15.7% versus 6.7% for E99K1
versus E99K1-Corr and 17.4% versus 10.3% for NC-Edit-
E99K versus NC (Figure 5E). Although there was no differ-
ence in R-GECO1 signal amplitude (F/F0) between E99K1
lines, NC-Edit-E99K hiPSC-CMs displayed a 50% lower
GEM-GECO signal amplitude (F/F0) relative to NC controls
(Figure S4G), indicating a lower systolic Ca2+ peak. These
data demonstrated both the E99K1 and NC backgrounds
to exhibit increased arrhythmogenic events when the
E99K-ACTC1 mutation is present.
E99K-Associated Abnormal Ca2+ Handling Is Absent
when Introduced into Healthy Genetic Background
Due to its key regulatory role in excitation-contraction
coupling, abnormal Ca2+ handling can contribute to severe
disease phenotypes. HCM patients can exhibit prolonged
Ca2+ transients (Lan et al., 2013), often attributed to the
presence of sarcomeric protein mutations, such as E99K-
ACTC1. Indeed, previous models have shown the E99K-
ACTC1 mutation to increase Ca2+ sparks and Ca2+ tran-
sients in young transgenic mice (Rowlands et al., 2017).
To investigate whether abnormal Ca2+ handling could be
detected, we used the CellOPTIQ cardiomyocyte analysis
platform to assess intracellular Ca2+ transients in 2D cul-
tures. Monolayers of hiPSC-CMs were loaded with Fluo4-
AM, and Ca2+ transients were recorded using CellOPTIQ
technology (Figure 6A). This 2D system showed that time
to peak (TTP) was significantly altered (p < 0.001) in the
E99K1 isogenic pair, with E99K1 exhibiting 115% longer
TTP than E99K1-Corr. NC-Edit-E99K and NC did not differ
(Figure 6B). Ca2+ transient decline was measured as time
from peak to 90% return to baseline (CTD90). Analysis
showed differences only in the E99K1 isogenic pair, with
E99K1 exhibiting a 31.4% change relative to E99K1-Corr
(Figure 6C).
Our earlier observations showed that contraction forces
and arrhythmogenic events varied with differing extracel-
lular Ca2+ concentrations (Figures 4A, 4B, and 5D).
Therefore, Ca2+ transient analysis was carried at a range
of extracellular Ca2+ concentrations to determine whether
the abnormal transient decline was also dependent on the
ability to handle extracellular Ca2+. Although all lines
exhibited prolonged CTD90 at lower extracellular Ca
2+ con-
centration (Figure 6D), there was no difference in response
to these changes between theNC isogenic lines. The higher
CTD90 increase in E99K1 compared with E99K1-Corr was
significant at lower than physiological Ca2+ concentrations
(0.5–1 mM).
Figure 5. Arrhythmic Event Frequency in 3D hiPSC-CM EHTs and in 2D GECI Targeted hiPSC-CMs
In (Ai) and (Aii), example traces of arrhythmic contractions are shown. In (B), analysis of an example trace in pClamp is shown with arrows
pointing to abnormal contractions identified through using a baseline and contraction count line. In (C), EHTs were stimulated at 1 Hz,
(legend continued on next page)
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We investigated the effect of a 3D environment architec-
ture on mutant Ca2+ transients. EHTs were loaded with the
Ca2+ indicator, Fluo4-AM, and stimulated at 1 Hz in Ty-
rode’s solution at 37C. Ca2+ transient parameters were ob-
tained through analysis of Ca2+-dependent changes in fluo-
rescence intensity within tissues. In 3D tissues there was no
significant difference in TTP caused by the presence of the
E99K-ACTC1mutation (Figure 6E), but CTD90 data showed
the same trend as the 2Dmodel. In 3D EHTs, E99K1 CTD90
was 81.5% longer compared with E99K1-Corr, while NC-
Edit-E99K and E99K2 showed no difference (Figure 6F).
Collectively, both 2D and 3D data showed that the E99K-
ACTC1 mutation caused abnormal Ca2+ handling in the
genetic background of E99K1 but not in NC or E99K2.
Targeting Ca2+Handling Pathways to Reduce
Hypertrophic Signaling
To investigate whether the difference in phenotype
severity was related to known hypertrophic signaling, we
took forward isogenic pairs for E99K1 and NC. We investi-
gated the expression of BNP because it has been reported to
be >100-fold elevated in the plasma of HCM patients
(Gardner, 2003). High-content imaging was used to clas-
sify cells in high, low, or negative BNP-expressing popula-
tion, using predetermined empirical thresholds previously
described for assessing BNP in hiPSC-CM lines (Carlson
et al., 2013).
Analysis of BNP/cTnT/DAPI immunostained hiPSC-CMs
(Figures S5A and S5B) showed no difference in BNP expres-
sion between NC-Edit-E99K and NC. In contrast, highly
significant (p < 0.001) differences were seen in all three
BNP populations for E99K1 versus E99K1-Corr, wherein
E99K1 was 6.92- and 2.97-fold higher for BNP-high and
-low cells, respectively, but 6.12-fold lower for BNP-nega-
tive cells. Thus, enhanced BNP expression in E99K-
ACTC1 was only seen in the E99K1, but not NC genetic
background, consistent with the difference in phenotype
severities found for Ca2+ transients and contractility.
Wehypothesized that the enhanced BNP expression seen
in E99K1 could also be influenced by extracellular Ca2+, as a
mechanism behind its abnormal phenotypes. Althoughwe
observed no change in BNP expression at extracellular Ca2+
spanning physiological levels (1.8mM), a reduction of BNP
expression was observed in 0.1 mM and 0.5 mM Ca2+ (Fig-and arrhythmic events were counted and expressed as a percentage for
In (D), arrhythmic events were counted in EHTs and expressed as a
E99K1 (Di, n = E99K1 7, E99K1-Corr 2), NC (Dii, n = 7 NC-Edit-E99K, 7
hiPSC-CMs utilized genetically encoded expression of R-GECO1.0 or rati
Ca2+ transient events occurring during a 300-s line scan, with events
isogenic lines. E99K1-Corr n = 4, E99K1 n = 5, NC n = 4, NC-Edit-E99K
All error bars represent SEM. Significance was determined by Student’s
E99K; black, wild-type. See also Figure S3B.
1234 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018ures S5C and S5D), indicating a role of Ca2+ in hypertro-
phic signaling pathways.
To investigate whether abnormal regulation of Ca2+
signaling pathwaysmay be contributing to themechanism
of disease phenotypes in E99K-ACTC1 mutants, we next
determined the expression levels of key Ca2+ signaling
genes through a targeted qRT-PCR screen (Figure 7A). Anal-
ysis showed no differences between NC-Edit-E99K and NC.
In contrast, E99K1 showed significantly (p < 0.05) lower
expression of calmodulin (CALM1) and calmodulin-depen-
dent protein kinase II delta (CAMK2D) than E99K1-Corr.
Although no difference was seen in expression of the
Ca2+-binding regulatory subunit of calcineurin (PPP3CB),
expression of the calmodulin-binding catalytic subunit
of calcineurin (PPP3CA) was significantly (p < 0.01)
lower in E99K1 than in E99K1-Corr. The greatest difference
was seen in the expression of the sarcoplasmic reticulum
Ca2+-binding calsequestrin 2 protein (CASQ2), with
E99K1 showing 5.25-fold lower levels than E99K1-Corr.
Expression of genes encoding the voltage-dependent Ca2+
channel (CACNA1C), the Ca2+ release inhibitor, phospho-
lamban (PLN), and the Ca2+-sensitive cysteine protease,
calpain 1 (CAPN1), did not differ between E99K1 and
E99K1-Corr (Figure 7). This expression data associated
well with the differences seen in disease phenotype be-
tween the donors and suggests a key role for Ca2+ signaling
pathways in disease penetrance.
Altogether, these data suggested that targeting cytosolic
Ca2+ levels, and specifically targeting sarcoplasmic reticu-
lum Ca2+, release may reduce hypertrophic signaling. As
such, ranolazine and dantrolene were identified as candi-
dates with potential therapeutic benefit. Treatment with
10 mM of either drug significantly reduced BNP expression
(p < 0.01) in all four lines, with the exception of dantrolene
on NC-Edit-E99K (Figure 7B). Interestingly, in almost all
cases, combined treatment with both drugs had a signifi-
cantly greater effect (p < 0.05) than a single-drug regimen.DISCUSSION
HCM is the most common inherited cardiomyopathy and
has been investigated using in vitro systems and transgenic
small animals. However, the relevance of these studies toE99K1 (Ai, n = 10, 10), NC (Ci, n = 11, 11), and E99K2 (Bi, n = 8, 5).
percentage during exposure to increasing Ca2+ concentrations, for
NC), and E99K2 (Diii, n = E99K2 5, E99K2-Corr 7). For 2D analysis
ometric GEM-GECO from the AAVS1 locus. In (E), analysis of irregular
lower than 75% mean peak amplitude, is shown for E99K1 and NC
n = 4.
t test, *p < 0.05, **p < 0.01, and ***p < 0.001. Red, mutant ACTC
(legend on next page)
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HCM in the human heart is not known. Study of HCM in
human heart has been limited due to the difficulties in ob-
taining fresh tissue. Therefore, HCM mutations in the
context of patient-derived hiPSC-CMs are important for
understanding the disease phenotype.
We investigated hiPSC derived from threemembers of an
extended family with the E99K-ACTC1 mutation (father
and son with the mutation and brother non-carrier). We
used CRISPR/Cas9 to create isogenic pairs of all three in
which the mutation had been corrected or introduced to
develop a physiologically relevant humanized E99K-
ACTC1 model. This gave us a toolset of six hiPSC-CM lines
that have enabled us to distinguish direct mutant-depen-
dent effects from secondary effects related to patient
age or genetic background that may affect the phenotypic
expression of HCM. The use of isogenics proved to be
crucial because our original hypothesis proved to be incor-
rect; namely, that phenotypic aberration would be consis-
tent between all E99K-expressing lines. While pathogenic
phenotypes were often observed in E99K1 hiPSC-CMs
(father), only some, and most notably arrhythmias, were
evident in the E99K2 and NC-Edit-E99K lines created
from his sons.
The Cell Lines
Heterozygous hiPSC-CM from E99K1 and E99K2 showed
expression of the E99K mutation, detected by mutation-
specific antibody as did the CRISPR/Cas9-converted
hiPSC-CM from NC. Interestingly, the expression of the
mutation was segregated with 50% of cells expressing
E99K and 50% of cells not expressing it. This indicates a
stochastic monoallelic expression of ACTC1 (Eckersley-
Maslin and Spector, 2014). A similar monoalleleic expres-
sion of myosin heavy chain mRNA was suggested for the
MYH7 R273G mutation (Kraft et al., 2016).
The significance of this is unknown but may be worth
further investigation. In particular it has been speculated
that a mosaic of wild-type and mutant cells having
different contractile properties could disrupt cell-cell me-
chanical interactions and be the trigger for myocyte
disarray and the subsequent interstitial fibrosis (Kraft
et al., 2016). Interestingly, it is already known that in car-
diac muscle the skeletal and cardiac actin isoforms are ex-Figure 6. Ca2+ Handling Properties in 2D hiPSC-CMs and 3D EHTs
hiPSC-CMs were loaded with Fluo4-AM and Ca2+ transients were recorde
determined in each of the four lines (Bi and Bii). Technical n = 36. Ca2
percentage of peak at 90% (Ci and Cii). Technical n = 36. Analysis w
centrations in Tyrode’s solution (Di and Dii). n = 6. For 3D hiPSC-CM ana
solution at 37C, and Ca2+ transients were recorded. EHT time to peak
decline was measured in each of the six lines as a percentage of peak
All error bars represent SEM. Significance was determined by Student’s
wild-type.
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percentage ofmutation expressed is proposed to be compa-
rable with the pathological distribution of mutant to wild-
type protein within the hearts of individuals affected with
heterogeneous autosomal dominant cardiac disease: The
50% overall expression of the mutant protein compares
with measurements of 39% (left ventricular free wall) and
19% (atrial-ventricular septum) in biopsies of two E99K pa-
tients (Song et al., 2011).
Contractility
In the transgenic mouse model, the E99K mutation
increased myofilament Ca2+-sensitivity of isometric force
about 2-fold (Song et al., 2011). When EHT are activated
maximally at 1.8 mM Ca2+ the maximum contraction,
which in this case is auxotonic rather than isometric,
ranged from 0.1 to 0.2 mN. There did not appear to be
any detectable difference between native and CRISPR/
Cas9 edited wild-type or E99K lines isogenic pairs. How-
ever, a large shift in [Ca2+] dependence was detected in un-
edited lines, with E99K EHTs having stronger contractions
at lower levels of external Ca2+. The millimolar concentra-
tion of Ca2+ in the medium is indirectly related to the
micromolar [Ca2+] in the sarcoplasm that activates contrac-
tion. It was observed that the threshold [Ca2+] to activate
contraction was lower for the unedited E99K mutant
samples. Similarly, the EC50 of E99K EHTs was lower than
that of the wild-type. This is compatible with the well-
documented enhanced myofibrillar Ca2+ sensitivity of the
E99K mutation in vitro and in the mouse model.
NC-Edit-E99K and E99K2 both had longer contraction
times and decreased velocity of contraction compared
with their isogenic controls. Both these isogenic pairs had
the same phenotype even when one had the mutation
knocked in and one had the mutation corrected. E99K1
has a high contraction rate. Analysis of sarcomere assembly
showed a trend, albeit non-significant, toward increased
disarray in E99K-expressing hiPSC-CMs (Figure S7). How-
ever, there was no apparent correlation between this
parameter and the contraction measurements recorded.
For comparison with E99K transgenic mice, we see
about 2-fold slower relaxation times but similar contrac-
tion times in isolated myofibrils, papillary muscle, andd using CellOPTIQ technology (Ai and Aii). Time to peak (TPeak) was
+ transient decline was measured in each of the DI and DII lines as a
as carried out on contractions during exposure to varied Ca2+ con-
lysis, EHT were loaded with Fluo4-AM, stimulated at 1 Hz in Tyrode’s
was determined in each of the six lines (Ei–Eiii). EHT Ca2+ transient
at 90% (Fi–Fiii). n = 3 for all apart from E99K2 where n = 5.
t test, **p < 0.01 and ***p < 0.001. Red, mutant ACTC E99K; black,
(legend on next page)
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cardiomyocytes, compatible with a longer overall twitch
time (Song et al., 2013; Rowlands et al., 2017). Moreover,
recombinant human E99K actin also shows decreased asso-
ciation, dissociation, and slower velocities of interaction
with myosin than wild-type (Bookwalter and Trybus,
2006).
Arrhythmia and Ca2+ Handling
ECG abnormalities are a hallmark of HCM and are
commonly observed in the E99K patient cohort (Monserrat
et al., 2007). The increased myofilament Ca2+ sensitivity
caused by HCM mutations alters intracellular Ca2+-buffer-
ing(Robinson et al., 2018), and this has been shown to be
sufficient to provoke arrhythmia and ECG abnormalities
in mice (Huke and Knollmann, 2010). An enhanced
probability of arrhythmia has also been observed with
the E99K mutation in transgenic mice (Song et al., 2011).
Moreover, an increase in Ca2+ sparks and Ca2+ transients
was observed that showed variable penetrance depending
on background mouse strain (Rowlands et al., 2017). This
trait was apparent in our hiPSC-CM EHTs: contractile
arrhythmia increased at higher [Ca2+] in both wild-type
and E99K, but E99K EHTs showed a significantly greater
frequency of arrhythmogenic events. This was further
confirmed by studies using GECI Ca2+ sensors in 2D
culture.
The difference in phenotype severity between the donors
(E99K1 and NC) associates with expression of the natri-
uretic peptide, BNP, a known marker of hypertrophy.
Expression was shown to be modulated by extracellular
Ca2+ levels, indicating a regulatory role of Ca2+ in hypertro-
phic response. Subsequent analysis identified abnormal
expression of calmodulin signaling pathway components
in the severe, but not the mild, phenotype. This pathway
is considered to be the primary sensor of changes in cellular
free Ca2+ levels. As such, reduced expression of calmodulin,
and the Ca2+sensitive enzymes it activates (CaMKII and
calcineurin), is likely to reduce the regulation of Ca2+
handling that is crucial for normal cardiac function. This
pathway has previously been implicated in hypertrophy
through its ability to regulate natriuretic peptide expres-
sion (Dewenter et al., 2017), supporting the hypothesis
that abnormal Ca2+ regulation in E99K1 is the mechanism
behind the greater severity of hypertrophic phenotype.
Interestingly, the greatest expression difference between
the E99K1 isogenic lines was in CASQ2 expression. Calse-Figure 7. Ca2+ Signaling in Hypertrophic hiPSC-CMs
(A) qPCR analysis of Ca2+ signaling gene expression ratios in E99K lin
(B) The effect of two intracellular Ca2+-altering drugs (ranolazine and
(C) Intracellular Ca2+ signaling pathways and the mechanism ranolazin
Ca2+ exchanger; SR, sarcoplasmic reticulum.
Significance was determined by Student’s t test, *p < 0.05, **p < 0.0
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plasmic reticulum. Reduced levels of calsequestrin 2 have
been shown to increase the probability of spontaneous
Ca2+ release for any given luminal free Ca2+ concentration
(Faggioni and Knollmann, 2012). Coupled with reduced
calmodulin-driven Ca2+ regulation, a cellular environment
with increased Ca2+ release from the sarcoplasmic reticu-
lumwould further exacerbate the hypertrophic phenotype
seen in E99K1.
The Origin of Phenotypic Variability
The common features of the E99K hiPSC-CM are
compatible with the known role of the mutation in
increasing myofilament Ca2+-sensitivity and disrupting
Ca2+ handling. However, there was considerable variability
between the three patient samples, with E99K1 showing
the greatest array of severe phenotypes. This may reflect
pathophysiology and/or age, particularly given that HCM
typically becomes symptomatic in the 2nd and 3rd decades
of life. E99K1 was 48 years old with overt symptoms of
HCM and LVNC, and conduction deficit, and thus is likely
to have developed secondary abnormalities (Figure S1). In
contrast, E99K2 was 19 years old and did not show
abnormal ECG abnormalities. NC was 14 years old and,
in this case, the mutation was introduced after the sample
was taken, so one would expect there to be no secondary
abnormalities.
Mutation load inmitochondrial DNA is higher in hiPSCs
produced fromolder individuals (Kang et al., 2016). An age-
dependent increase in mitochondrial DNA mutations,
leading to increased reactive oxygen species production
and activation of hypertrophic signals, has been proposed
as the mechanism behind an age-dependent development
of a cardiac hypertrophic phenotype (Marian, 2001).
Mouse models have previously shown age to influence
E99K-ACTC1-associated phenotypes, with older E99K-
ACTC1 mice developing increased end-diastolic and end-
systolic volumes (Song et al., 2011).
Thus, speculatively our model recapitulates a varied
phenotype severity through an age-dependent, rather
than a genetic background, based mechanism.
Limitations of the hiPSC System for This Study
We minimized technical variation by choosing directly
related family members, from whom biopsies were
harvested, prepared, and reprogrammed to hiPSC at thees normalized to wild-type (WT) controls.
dantrolene) on the percentage of highly expressing BNP hiPSC-CMs.
e and dantrolene reduce cytoplasmic Ca2+ levels. n = 3. NCX, sodium-
1, and ***p < 0.001. Red, mutant ACTC E99K; black, wild-type.
same time using the samemethods; this extended to differ-
entiation method, stage of differentiation, and cardiomyo-
cyte purity, with cultures typically containing >90% a-acti-
nin-positive cells (e.g., Figures 1 and 2). Assays were run on
the same day wherever possible. Two clones per isogenic
sets were used, wherein off-target events were not detected
and genetic stability was retained, at least at the resolution
of G-banding karyogram of 30 metaphase spreads. Never-
theless, any cells undergo stochastic epigenetic/genetic
change relative to time in culture (Allegrucci et al., 2007;
Smith and Whitney, 1980), with an additional issue for
hiPSC being the retention of residual epigenetic memory
that is refractory to reprogramming (Peng et al., 2011; Row-
lands et al., 2017).
Differentiation was highly efficient, but the effect of the
residual 1%–10% non-cardiomyocytes, which include
mesodermal derivatives such as fibroblasts and smooth
muscle cells (Sharma et al., 2015), can influence cell
function. Deliberate mixing of hiPSC-CMs with non-cardi-
omyocyte populations (e.g., endothelial cells and fibro-
blasts) is known to alter force generation and drug
responses (Ravenscroft et al., 2016). Purity of hPSC-CMs
can be improved by techniques such as metabolic or ge-
netic selection (Anderson et al., 2007; Sharma et al.,
2015). However, these approaches place additional stress
on the cardiomyocytes, are cumbersome, and/or require
additional prolonged culture periods to genetically
engineer individual hiPSC lines, which risks introducing
further epigenetic/genetic change.
The ideal way to overcome these limitations is to increase
the number of hPSC lines within the study and ensure each
is matched with a Cas9/CRISPR isogenic control. However,
there are currently no reports of high-volume hiPSC pro-
duction, with multiple clones and isogenic pairing, likely
due to the labor required for such an initiative.
Finally, it is well established that hiPSC-CMs immature
relative to adult cardiomyocytes (see, e.g., Denning et al.,
2016 for review). This includes the machinery that under-
pins HCM, including Ca2+ handling, t-tubules, sarcomeric
alignment, and mitochondrial content. Despite these
deficiencies, hiPSC-CMs are becoming established as a mo-
dality to evaluate successfully the impact of disease and
drugs on cardiomyocyte function (Mosqueira et al., 2018;
Gintant et al., 2017). The concerted international effort
to improve hiPSC-CM maturity via approaches such as
metabolic switching (Correia et al., 2017) and electrical
pacing (Sun andNunes, 2016) will further advance the util-
ity of these models.
The Use of E99K hiPSC-CM in Drug Screening
Figure 7C shows an overview of cytosolic Ca2+ released
from the sarcoplasmic reticulum, activating calmodulin-
dependent signaling pathways, that ultimately alters geneexpression. Blocking sarcoplasmic reticulum Ca2+ release
through inhibiting the ryanodine receptor-2 with dantro-
lene, and promoting Ca2+ efflux through enhancing the
sodium-Ca2+ exchanger with ranolazine, lowers cytosolic
Ca2+ and reduces hypertrophic signaling. We demon-
strated that targeting of intracellular Ca2+ levels, by pro-
moting Ca2+ efflux (ranolazine) and limiting sarcoplasmic
reticulum Ca2+ release (dantrolene), reduced hypertrophic
signaling.
Ranolazine was identified as a therapeutic candidate as
an enhancer of the sodium-Ca2+ exchanger (outward
mode) by blocking late sodium current and thereby indi-
rectly promoting Ca2+ efflux. Contrastingly, the mode of
action for dantrolene directly limits Ca2+ release from the
sarcoplasmic reticulum during systole through its activity
as a ryanodine receptor antagonist. These drugs have previ-
ously been shown to have a potential benefit in other HCM
models, with ranolazine used to ameliorate diastolic func-
tion in HCM patient-derived cardiomyocytes (Coppini
et al., 2012), and dantrolene applied as an antiarrhythmic
agent in mouse models of HCM (Jung et al., 2012; Okuda
et al., 2018). Here we show these drugs to have potential
benefit in cases of E99K-ACTC1-associated HCM, and our
results indicate that a dual treatment targeting both
mechanisms may have enhanced therapeutic benefit.
Dual treatments such as this have not been reported
clinically and, as such, hiPSC-CMs provide an opportunity
to trial new combinations with potential patient benefit.
Moreover, the model we present now provides opportu-
nities for high-throughput and/or high-content evaluation
of the ability of drugs, singly or in combination, to rescue
the phenotypes identified, particularly using hiPSC-CMs
derived from the heterozygote father E99K1.EXPERIMENTAL PROCEDURES
hiPSC Generation
Fibroblast cultures were expanded in fibroblast growth medium
and transduced using CytoTune2.0-iPS Sendai Reprogramming
(Thermo Fisher #A16517). Following transduction, cultures were
changed to Essential 6 medium (Life Technologies #A1516401)
supplemented with 100 ng/mL basic fibroblast growth factor
(Peprotech #100-18B) andmedium exchanged daily until colonies
appeared (5–10 days), after which the medium was changed to
Essential 8 medium (Life Technologies #A1517001). hiPSC col-
onies were expanded and isolated by manual dissection. Two
clones were used per line and used in subsequent studies.
CRISPR/Cas9 Genome Editing of hiPSC
The strategy for correcting/introducing the E99K-ACTC1mutation
to generate isogenic control lines has been previously described in
detail (Kondrashov et al., 2018). In brief, an ACTC1 targeting vec-
tor was constructed containing a dual drug selection cassette (Puro-
DTK) flanked by PiggyBac recombination sites, and the two ACTC1Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018 1239
sequences (1 kb upstream and 1 kb downstream) homologous
to the endogenous target locus cut site. One microgram of
ACTC1 targeting vector was transfected into 1 3 106 hiPSCs,
with 1 mg of hCas9 plasmid and 1 mg of guide RNApU6 vector using
an Amaxa 4D system (Lonza). Twenty-four hours after transfec-
tion, the medium was supplemented with 0.25 mg/mL puromycin
(Life Technologies #A1113802) for positive selection of clones for
up to 2 weeks. The puromycin-positive clones were then harvested
using TrypLE (Life Technologies #12563029), cultured for 24 hr,
and transfected with 3 mg of transposase plasmid transfection
using Fugene HD transfection reagent (Promega #E2311). On the
next day, cells were exposed to medium containing 2 mg/mL gan-
ciclovir (Sigma #G2536) for negative selection of PiggyBac excision
clones for up to 2 weeks.Monolayer Cardiac Differentiation of hiPSCs
hiPSC differentiation was performed by seeding vessels at approx-
imately 20,000–40,000 cells/cm2, as described above. Fresh E8 was
added the next day and the pre-conditioning step of hiPSC was
performed the day after, by adding a Matrigel overlay (Matrigel
diluted 1:100 in StemPro34 Serum Free Medium [SP34, Gibco
#10639011]), supplemented with 1 ng/mL BMP4 (R&D Systems
#314-BP-050). Approximately 16 hr later, medium was replaced
by SP34 supplemented with 8 ng/mL activin A (ActA, Life Technol-
ogies #PHC9564) and 10 ng/mL bone morphogenetic protein 4
(BMP4). Forty-eight hours later, medium was changed to RPMI
supplemented with B27 without insulin (INS, Life Technologies
#A1895601) and KY0211 (R&D #4731) and XAV939 (R&D
#3748), both at 100 mM. These small molecules were added again
2 days later, in RPMI supplemented with B27 with insulin (+INS,
Life Technologies #0080085-SA) instead. Thereafter, medium was
changed every 2–3 days by fresh RPMI + B27 + INS until day 15
of differentiation, when spontaneously beating hiPSC-CM
were dissociated and replated as below, and kept in RPMI + B27 +
INS for approximately 10 days until phenotypic assays were
performed.hEHT Fabrication and Maintenance
hEHTs were fabricated as previously described (Breckwoldt et al.,
2017; Schaaf et al., 2014). In brief, Teflon spacers (EHT Technolo-
gies #C0002) were inserted in 2% ultra-pure agarose (Invitrogen
#15510-027) solution pipetted into 24-well plates (Nunc) before
gelification. Thereafter, spacers were removed and silicone racks
(EHT Technologies #C0001) were placed in the aperture left by
the agarose casting molds. Subsequently, freshly dissociated
hiPSC-CMs were resuspended in DMEM (Biochrom, F0415), sup-
plemented with 10% heat-inactivated fetal calf serum (Biochrom
#S0615), 1% penicillin/streptomycin (PEST, Gibco), 2 mM L-gluta-
mine, 23 DMEM (equalizing the hypotonic volume of fibrinogen
plus thrombin), 10%Matrigel, 0.1% Y-27632, and 5mg/mL fibrin-
ogen (Sigma #F8630). The CM fibrinogen mix was then quickly
mixed with 3 U of thrombin (Sigma #T7513) and pipetted into
the aperture between the silicone posts. Forming hEHTs were
then incubated for 2 hr at 37C and 7% CO2 and subsequently
moved to new 24-well plates filled with DMEM supplemented
with 10% horse serum, 10 mg/mL insulin (Sigma #I9278),
33 mg/mL aprotinin (Sigma #A1153), and 1% (v/v) PEST, termed1240 Stem Cell Reports j Vol. 11 j 1226–1243 j November 13, 2018EHT medium. Each hEHT consisted of 1 million cells and was fed
every other day for 2–3 weeks.
Analysis of hEHTs
Contractile forcewas analyzed as previously described (Mannhardt
et al., 2016). In brief, 2- to 3-week-old hEHTs were immersed in
modified Tyrode’s solution (120 mM NaCl, 5.4 mM KCl, 1 mM
MgCl2, 0.4 mM NaH2PO4, 22.6 mM NaHCO3, 5 mM glucose,
0.05mMNa2EDTA, and 25mMHEPES) and variedCa
2+ concentra-
tion (0–5 mM CaCl2), and the 24-well plate was placed inside a
transparent chamber to maintain homeostatic temperature
(37C), CO2 (5%), and O2 (40%). Automated video-optical record-
ings of silicone post deflectionwere enabled by the EHTanalysis in-
strument (EHT Technologies #A0001) whereby a video camera
placed above the chamber tracked hEHTmovement and a separate
computer running a customized software (CMTV GmbH) deter-
mined contractile force based on the knownmechanical properties
of the silicone posts. When indicated, EHTs were electrically paced
(2 V, 1–2Hz, impulse duration 4ms) with carbon electrodes using a
Grass S88X stimulator (Astro-Med). The contraction peaks were
analyzed in terms of force, and contraction (T1) to peak from
20% peak height and relaxation time (T2) from peak to 80% of
peak height. To quantify arrhythmogenic events without bias,
we used pClamp software to identify the number of abnormal con-
tractions compared with normal baseline events.
Statistics
Statistical analysis was performed using GraphPad Prism (v7,
GraphPad, La Jolla, CA, USA) software, evaluated by Student’s
t tests or unpaired one-way ANOVA, to compare isogenic pairs or
between genotypes. Differences were considered significant at
*p < 0.05, **p < 0.01, and ***p < 0.001. Numbers denoted ‘‘n’’ indi-
cate independent experiments unless stated otherwise.
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